Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Duloxetine 60 MG Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stepped Care for Depression and Musculoskeletal Pain

NCT00118430
View directory record Official record
Conditions
Pain, Depression
Interventions
Stepped Care, Antidepressants, Usual Care
Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 4, 2026, 6:59 PM EDT
Recruiting Not applicable Interventional

Algorithm-informed Decision-making to Advance Pain Treatment

NCT07731750
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Algorithmically informed randomization (taking into account phenotypes), Physical Therapy (PT) and Exercise, Cognitive-Behavioral Therapy for Pain (PRISM-CBT), mHealth Acupressure Self-Management:, Duloxetine
Device · Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 4, 2026, 6:59 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

NCT05120934
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome

NCT01237587
View directory record Official record
Conditions
Fibromyalgia
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Loma Linda, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

NCT02058693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
mixed salts amphetamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 4, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

NCT01288079
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TC-5214, Duloxetine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 3 Interventional

Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder

NCT00122863
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Duloxetine Hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
19
States / cities
Sherman Oaks, California • Fort Myers, Florida • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2007 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)

NCT03315533
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
Duloxetine 30 milligrams (MG), Duloxetine 60 milligrams (MG), Placebo Oral Tablet
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

NCT01153009
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Vortioxetine, Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
56
States / cities
Beverly Hills, California • Chino, California • Garden Grove, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study in the Treatment of Children and Adolescents With Major Depressive Disorder

NCT00849693
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, fluoxetine, duloxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
44
States / cities
Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

A Study of Duloxetine in Major Depressive Disorder (MDD) and Associated Painful Symptoms

NCT01000805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Beverly Hills, California • Sherman Oaks, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Not applicable Interventional Results available

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

NCT01028352
View directory record Official record
Conditions
Breast Cancer
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis

NCT01018680
View directory record Official record
Conditions
Osteoarthritis Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
32
States / cities
Tucson, Arizona • Garden Grove, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain

NCT00507936
View directory record Official record
Conditions
Diabetic Neuralgia, Diabetic Neuropathies, Diabetic Neuropathy, Painful, Diabetic Polyneuropathy, Neuralgia, Diabetic
Interventions
ABT-894, placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 4, 2026, 6:59 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107
View directory record Official record
Conditions
Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Interventions
Oxaliplatin, Duloxetine Hydrochloride, Duloxetine, Quality-of-Life Assessment, Questionnaire Administration, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
792
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 525 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)

NCT03575403
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Alcohol, Placebos, Duloxetine (60 MG), Methylphenidate, Duloxetine (30 MG)
Drug
Lead sponsor
Craig Rush
Other
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 4, 2026, 6:59 PM EDT
Terminated Phase 2 Interventional Results available

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

NCT01145755
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AZD2066, Placebo, Duloxetine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
13
States / cities
Garden Grove, California • San Diego, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 4 Interventional

A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression

NCT00296699
View directory record Official record
Conditions
Atypical Depression
Interventions
Duloxetine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 4, 2026, 6:59 PM EDT
Not listed Phase 2 Interventional

Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

NCT03812523
View directory record Official record
Conditions
Chemotherapy-Induced Peripheral Neuropathy
Interventions
Duloxetine 60 mg qd, Lorcaserin
Drug
Lead sponsor
Southeastern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Newnan, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

NCT01564862
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
vortioxetine (Lu AA21004), Duloxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
62
States / cities
Tucson, Arizona • Little Rock, Arkansas • Bellflower, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 2 Interventional

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Test the Use of Duloxetine for Pain in MS

NCT00457730
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Brown, Theodore R., M.D., MPH
Individual
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Effect of Combined Morphine and Duloxetine on Chronic Pain

NCT03249558
View directory record Official record
Conditions
Chronic Low Back Pain, Chronic Neck Pain
Interventions
Morphine, Duloxetine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 4, 2026, 6:59 PM EDT
Completed Phase 4 Interventional Results available

Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations

NCT02260388
View directory record Official record
Conditions
Cryptogenic Sensory Polyneuropathy
Interventions
Nortriptyline, Duloxetine, Pregabalin, Mexiletine
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
30 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 4, 2026, 6:59 PM EDT